S05590 is a fixed-dose combination of perindopril tert-butylamine 4 mg/indapamide 1.25 mg, and S06593 is a fixed-dose combination of perindopril arginine 5 mg/indapamide 1.25 mg/amlodipine 5 mg. The purpose of this study was to determine whether there were pharmacokinetic interactions between the components of S06593, which uses S05590 and amlodipine as reference drugs in Chinese healthy male volunteers after a single oral administration under fasting conditions. Thus, a single-center, open-label, randomized, three-period, six-way crossover study was conducted. A total of 42 subjects were enrolled and randomized to receive S05590 plus amlodipine, or S06593. The doses of perindopril were 3.34 mg in both S05590 and S06593 calculated as free acid. Blood samples were collected in each treatment period to determine the plasma concentrations of perindopril, indapamide, amlodipine, as well as perindoprilat, which is the main metabolite of perindopril. 39 subjects completed this study. The 90% confidence intervals of geometric mean ratios (GMRs) of Cmax, AUC0-t, and AUC0-∞ for perindopril, perindoprilat, indapamide and amlodipine were all within the limits (80.00-125.00 %), indicating that S05590 plus amlodipine and S06593 were pharmacokinetic equivalent. During the study, only one serious emergent adverse event (SEAE) was reported, which was considered as not related to study drug by the investigator. And there were no serious treatment-related adverse events in this study.